MENU
CRON
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CRON stock forecast, quote, news & analysis

Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development... Show more

CRON
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CRON with price predictions
Sep 25, 2026

Momentum Indicator for CRON turns positive, indicating new upward trend

CRON saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 106 similar instances where the indicator turned positive. In 88 of the 106 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +5.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 167 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

The Aroon Indicator entered an Uptrend today. In 97 of 127 cases where CRON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for CRON moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 14 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 49 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

CRON broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.151) is normal, around the industry mean (43.753). P/E Ratio (17.579) is within average values for comparable stocks, (141.508). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.147). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.1B. The market cap for tickers in the group ranges from 2.12K to 66.76B. MKKGY holds the highest valuation in this group at 66.76B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 42%. APUS experienced the highest price growth at 310%, while IMCC experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -46%. For the same stocks of the Industry, the average monthly volume growth was 45% and the average quarterly volume growth was 25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 55
SMR Rating: 86
Profit Risk Rating: 82
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
CRON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

pharmaceutical, medical marijuana, cannabis

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
4491 Concession Road 12
Phone
+1 416 504-0004
Employees
610
Web
https://www.thecronosgroup.com
Momentum Indicator for CRON turns positive, indicating new upward trend